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Abstract: Previous works have shown that differentiated HepaRG cells can exhibit drug metabolism 
activities close to those of primary human hepatocytes for several weeks at confluence. The present 
study was designed to evaluate their long-term functional stability and their response to repeated daily 
drug treatments over a 14-day period, using a transcriptomics approach. Our data show that less than 
1% of the expressed genes were markedly deregulated over this period and mainly included down-
regulation of genes related to the cell cycle during the two weeks and overexpression of genes involved 
in xenobiotic and lipid metabolism from 3 days. After daily treatment with the three PPAR agonists, 
fenofibrate, troglitazone and rosiglitazone qualitative and/or quantitative changes in gene profiling 
were observed depending on the compound and duration of treatment. The highest increase in the 
number of deregulated genes as a function of drug treatment was seen with rosiglitazone. The most 
up-regulated genes common across the three compounds were mainly related to lipid and xenobiotic 
metabolisms. All the data support the conclusion that human HepaRG cells have unique functional 
stability at confluence and that they are suitable for investigations on chronic effects of drugs and other 
chemicals. 
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Abstract 
Previous works have shown that differentiated HepaRG cells can exhibit drug metabolism 
activities close to those of primary human hepatocytes for several weeks at confluence. The 
present study was designed to evaluate their long-term functional stability and their response 15 
to repeated daily drug treatments over a 14-day period, using a transcriptomics approach. 
Our data show that less than 1% of the expressed genes were markedly deregulated over 
this period and mainly included down-regulation of genes related to the cell cycle during the 
two weeks and overexpression of genes involved in xenobiotic and lipid metabolism from 3 
days. After daily treatment with the three PPAR agonists, fenofibrate, troglitazone and 20 
rosiglitazone qualitative and/or quantitative changes in gene profiling were observed 
depending on the compound and duration of treatment. The highest increase in the number 
of deregulated genes as a function of drug treatment was seen with rosiglitazone. The most 
up-regulated genes common across the three compounds were mainly related to lipid and 
xenobiotic metabolisms. All the data support the conclusion that human HepaRG cells have 25 
unique functional stability at confluence and that they are suitable for investigations on 
chronic effects of drugs and other chemicals.  
 
Key words: HepaRG cells, Transcriptomics, PPAR agonists, Repeated treatments, 
Time-dependent changes, gene profiling 30 
 
Abbreviations: 
CYP, cytochrome P450; DMSO, dimethyl sulfoxide ; FBS, fetal bovine serum; LFC, log2 fold 
change; PPAR, peroxisome proliferator-activated receptor.
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Introduction 35 
The liver is the most complex and metabolically active organ in the human body; it performs 
hundreds of essential functions but is also affected by multiple diseases. The marked hepatic 
functional differences existing between human and laboratory animals have led to a growing 
interest for in vitro human liver cell preparations for investigations on normal and diseased 
human liver (Guguen-Guillouzo and Guillouzo, 2010). Primary hepatocytes are the closest 40 
model to the liver in vivo (Guillouzo, 1998). However, they exhibit large inter-donor variability, 
as evidenced by analysis of basal and chemical-altered gene expression profiles in 
hepatocyte populations from multiple donors using transcriptomic approaches (Rogue et al., 
2012). Indeed, it appears that, whatever the test chemical, only a very small set of 
responsive genes is reproducibly altered among hepatocytes from multiple individual donors 45 
(Goyak et al., 2008; Rogue et al., 2012). 
Liver cell lines are potential alternatives to primary hepatocytes. However, many studies 
have emphasized the poor resemblance between primary normal hepatocytes and liver cell 
lines, including their transcriptome (Boess et al., 2003; Hart et al., 2010; Jennen et al., 2010; 
Olsavsky et al., 2007). Nevertheless, there is presently one exception represented by the 50 
HepaRG cell line that can differentiate from a bipotent progenitor state to attain features of 
normal adult hepatocytes in primary culture without losing the indefinite growth property of 
immortalized cell lines (Cerec et al., 2007; Guillouzo et al., 2007). 
HepaRG cells have been shown to be a suitable in vitro cell model for studies on viral B 
infection and replication (Gripon et al., 2002) and xenobiotic metabolism and toxicity (Aninat 55 
et al., 2006; Antherieu et al., 2010; Antherieu et al., 2012). Recent studies have confirmed 
their resemblance to primary human hepatocytes by comparing their gene expression 
profiles either at the basal level or after chemical treatment using whole genome arrays, 
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suggesting that HepaRG cells could be representative of primary human hepatocyte 
populations (Lambert et al., 2009).  60 
Contrary to other liver cell lines which continue to grow and consequently do not remain 
functionally stable, HepaRG cells cease to proliferate at confluence. Moreover, they do not 
form tumors in nude mice (Cerec et al., 2007). Importantly, HepaRG cells maintain their 
xenobiotic metabolism capacity, including their responsiveness to prototypical inducers, for 
several weeks at confluence (Antherieu et al., 2010; Josse et al., 2008). However, their 65 
global long-term stability at the transcriptome level has not been evaluated yet. 
Within the 5-year EU framework PREDICT-IV, we performed a detailed comparative analysis 
of the transcriptome of HepaRG cells after 1, 3 and 14 days in basal and drug-treated 
conditions using Illumina microarrays. Three PPARs agonists, fenofibrate, troglitazone and 
rosiglitazone were used to evaluate drug-induced gene profiling changes related to repeated 70 
treatments. Our data show high reproducibility between different experiments, deregulation 
of few genes with time at confluence and some qualitative and quantitative changes in gene 
profiling depending on the PPAR agonist and the duration of treatment. 
Material and methods 
Reagents 75 
Williams‟ E medium was supplied by Eurobio (Les Ulis, France) and fetal bovine serum 
(FBS) was from HyClone® (Thermo Fischer Scientific, Illkrich, France). Troglitazone and 
rosiglitazone were purchased from Calbiochem. Fenofibrate were from Sigma Aldrich (St. 
Quentin Fallavier, France). All other chemicals were of the highest quality available. 
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HepaRG cell cultures 80 
In the present study, HepaRG cells were first seeded at a density of 2.6 x 104 cells/cm2 in 6-
well dishes in growth medium composed of Williams‟ E medium supplemented with 10% 
FBS, 2 mM glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin and 5x10-5 M 
hydrocortisone hemisuccinate. After two weeks of culture, they were shifted to the same 
culture medium supplemented with 2% dimethyl sulfoxide (DMSO) for two further weeks in 85 
order to reach maximum differentiation. At that time, differentiated HepaRG cell cultures 
were composed of both mature hepatocytes and primitive biliary epithelial cells (about 50% 
of each type) (Cerec et al., 2007). The cells were issued from the same cryopreserved cell 
stock (passage 10) and used at passage 12. 
Drug treatments  90 
Two days before treatment, differentiated HepaRG cells were shifted to a medium containing 
2% serum and 1% DMSO. In this medium CYP activities are still maintained at sufficient 
levels and protein binding of test drugs is usually limited. This medium was renewed daily. 
Cultures were treated with the PPAR alpha agonist fenofibrate, the two PPAR gamma 
agonists troglitazone and rosiglitazone or the vehicule (DMSO) every day for up to 14 days 95 
(Fig 1). In preliminary experiments their cytotoxicity was assayed using the MTT test to select 
appropriate drug concentrations. A 10% toxic concentration (TC10) was determined for each 
drug after 14-day repeated exposure and was used for all experiments, i.e. 30, 70 and 100 
µM for troglitazone, rosiglitazone and fenofibrate respectively. 
RNA isolation.  100 
HepaRG cells were used after 1, 3 and 14 days for transcriptomic analysis. Briefly, they were 
washed with phosphate buffered saline (PBS) 1X and harvested in lysis buffer (RLT buffer 
and β-mercaptoethanol). Total RNA was isolated using the RNeasy mini Kit (Qiagen, Venlo, 
Netherlands). RNA quantity and purity were assessed with a Nanodrop ND-1000 
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spectrophotometer (Nyxor Biotech, Paris, France) and RNA integrity was checked on a 105 
Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany). 
Microarray hybridizations.  
Gene expression analysis was performed using Illumina ® HT 12 v3 BeadChip arrays 
(Illumina Inc.) allowing the analysis of ~48,000 transcripts. Synthesis of biotin-labelled cRNA 
was performed in an automated procedure using a Theonyx Liquid Performer (Aviso GmbH,) 110 
and MessageAmp™ II aRNA amplification Kit (Ambion) with several modifications (Zidek et 
al., 2007). Instead of column cleanup, the bead-based Agencourt® RNAclean™ system 
(Beckman Coulter) was applied to purify cDNA and cRNA. cRNA quantity was measured 
spectrophotometrically (NanoDrop®) and the 2100 Agilent Bio-Analyzer was used for quality 
assessment. Amplified biotinylated cRNA (750 ng) was hybridized onto the Illumina® 115 
BeadChip in a Hybridization Cartridge under humidified conditions for 20 h at 58 °C. The 
chips were then washed, stained for 10 min with 1 µg/ml streptavidin-conjugated Cy3 
(Amersham Biosciences), and finally dried by centrifugation. Fluorescence detection was 
carried out by confocal laser scanning with the Illumina® BeadArray Reader (Illumina Inc) at 
532 nm and 0.8 µm resolution. Illumina® BeadStudio Software was used for condensing raw 120 
data and further to ensure array quality based on different control bead parameters as 
described in a previous study (Boehme et al., 2009). 
Data processing and statistical analysis 
Differences in gene expression measurements between corresponding time-matched vehicle 
controls and drug treatment conditions were summarized for each feature as log2 fold 125 
change (LFC) value and associated p-value computed by application of the moderated 
(unpaired) t-test (Smyth, 2004). The Benjamini-Hochberg multiple testing procedure 
(Benjamini and Hochberg, 1995) was applied to correct p-values for multiple testing of 
features. The R package „limma‟ (Smyth, 2005) was used for calculation. Differentially 
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expressed genes were selected with the adjusted p-value of 0.01 and LFC cutoff of 0.58 (fold 130 
change cutoff of 1.5). Genes with a LFC value larger than 0.58 were regarded as up-
regulated while genes with a LFC value smaller than -0.58 were regarded as down-
regulated. For each time point, pathway hypotheses were generated using the Ingenuity 
Pathway Analysis® v.7.0 software (IPA, Ingenuity System, CA). The names of all 
deregulated genes identified in the present study are given in the Supplemental Table 1. 135 
 
Results 
Inter-assays correlation coefficients  
A total of 48,000 probes, corresponding to 25,000 annotated genes, were present on each 
array. Seven independent experiments, each containing 2 to 8 technical duplicates, were 140 
performed over a 3-year period using cells derived from the same frozen cell stock at 
passage 12. Transcriptomes of differentiated cells maintained for 1, 3 and 14 days at 
confluence were analyzed. Correlation coefficients were high, ranging from 0.98 to 0.99 for 
technical and biological replicates (data not shown). Using an arbitrary cut-off of 6 (on log2 
data), the number of expressed genes varied between 12,791 and 13,536 and the lowest 145 
consistency did not fall below 88 % (Fig. 2A, B).  
Venn diagrams were drawn on the common expressed genes in all experiments; at the 3 
time points the number of expressed genes was very close representing 13,026, 13,027 and 
13,040 with 12,536 in common after 1, 3 and 14 days respectively (Fig. 2C). Hierarchical 
clustering showed that day 3 was closer to day 14 than to day 1 (Fig. 2C). Accordingly, 150 
principal component analysis did not allow to separate the 3 time points (Fig 2D).  
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Differential gene expression with time at confluence  
Differentially expressed genes of all the control samples are displayed in Figure 3. The total 
number of deregulated genes was 106; among them 54 were different between day 1 and 
day 3; 71 between day 1 and day 14 (34% up-regulated and 66% down-regulated) and 36 155 
between day 3 and day 14 (Fig. 3A). Taking into account only modulated genes, hierarchical 
clustering showed that day 1 was closer to day 3 than to day 14 (Fig. 3B).  
Three major functional pathways differed as a function of culture time, i.e. cell cycle, lipid 
metabolism and xenobiotic metabolism; between days 1 and 3 most deregulated genes, 
were down-regulated while between days 3 and 14 a set of up-regulated genes was 160 
identified in addition (Fig. 3C). Taking day 1 as a reference, most genes involved in cell cycle 
were down-regulated after 3 or 14 days (Fig. 3C; Supplemental Fig. 1A) while many of the 
up-regulated genes after 14 days were involved in lipid and xenobiotic metabolisms (Fig. 3C; 
Supplemental Fig. 1B). Up-regulated genes related to lipid metabolism included THRSP, 
APO2, 4 and 5, HSD17B13, CYP4A11 and those related to xenobiotic metabolism CYP2A6, 165 
2C18, 2C19, 3A4. Among other up-regulated genes were genes related to inflammation and 
stress (CRP, TMPRSS6, CD3D, INHBE), innate immunity (SKAP1, LEAP2) and transport 
(OSTalpha, SLC28A1, SLC7A9). The highest up- and down-regulated genes were THRSP 
(1.67 LFC corresponding to 3.2-fold change) and CDC20 (-1 LFC corresponding to 0.5-fold 
change) respectively.   170 
Influence of PPAR agonists on gene expression as a function of treatment duration  
In order to take into account time-related changes in gene expression profiles in untreated 
cultures changes in gene transcripts induced by the three PPAR agonists after 1, 3 and 14 
days of treatment were estimated by comparison with corresponding controls. Total and 
specific modulated genes are shown in Venn diagrams (Fig 4A). Thus, when considering the 175 
three time points a total of 99, 224 and 153 different genes with 20 genes in common was 
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modulated by fenofibrate, rosiglitazone and troglitazone (Fig. 4A), representing  47, 39 and 
15 commonly deregulated genes after 1, 3 and 14 days of treatment to the three PPAR 
agonists respectively (Fig. 4C). Noticeably, more commonly deregulated genes were 
observed between the two PPARγ agonists troglitazone and rosiglitazone (44) than between 180 
these two PPARγ agonists and the PPARα agonist fenofibrate, representing 19 and 7 genes 
with troglitazone and rosiglitazone respectively (Fig. 4A). The number of up- and down-
regulated genes was variable for each drug at the different time points (Fig. 4B, 
Supplemental Table 2). The total number was higher on day 14 than on days 1-3 for 
fenofibrate and especially rosiglitazone (Fig. 4B, Supplemental Table 2). 185 
Using the Ingenuity Pathway Analysis® software we found that the major “top networks” 
included lipid metabolism for the three compounds and in addition, drug metabolism for 
rosiglitazone and fenofibrate. The top “tox lists” included fatty acid metabolism, xenobiotic 
metabolism signaling, PXR/RXR activation at the three time points and in addition, LPS/IL1 
mediated inhibition of RXR function at day 14 for rosiglitazone, FXR//RXR et PXR/RXR 190 
activation, LPS/IL1 mediated inhibition of RXR function at the three time points for 
troglitazone; fatty acid metabolism, PXR/RXR activation, LPS/IL1 mediated inhibition of RXR 
function, at the three time points for fenofibrate. Analysis of gene profiles changes induced 
by the three PPARs also showed that a number of modulated genes were related to lipid and 
xenobiotic metabolisms (Fig. 5).  195 
Most deregulated genes by 100µM fenofibrate were up-regulated; they included genes 
involved in mitochondrial fatty acid oxidation and ketogenesis (CPT1A, HADHB, HADHB), 
peroxisomal β oxidation (ACOX1, PEX11A), microsomal ω oxidation (CYP4A11), fatty acid 
binding and activation (FABP4), regulation of lipoprotein lipase (ANGPTL4), associated with 
lipid droplets (PLINs) and transcriptional factors (KLF10, KLF11) as well as with 200 
glucose/glycerol metabolism (PDK4). Down-regulated genes were only 13, 17 and 20 after 1, 
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3 and 14 days of treatment; they included ADH4, GMNT and THRSP. Noteworthy, the 
number of deregulated genes increased only slightly between days 3 and 14 (81 versus 88); 
the main deregulated genes were found at the 3 time points and showed only limited 
variation, with the exception of THRSP which became repressed at day 3 and much more on 205 
day 14 (FLC: -2.6 versus -1.7). 
The percentage of down-regulated genes with 70µM rosiglitazone and 30µM troglitazone 
was much higher than with fenofibrate, whatever the duration of treatment. 
Various genes related to lipid metabolism including ANGPTL4, PLINs, PEX11A, DHRS9 
and/or to xenobiotic metabolism (CYP3A4, UGT1A1) were also up-regulated with 210 
rosiglitazone including at day 14 and with troglitazone after 1-3 days of treatment. However, 
some major qualitative and quantitative differences were observed between the two 
glitazones. CYP1A1, CYP1B1 and CPT1 were up-regulated only by rosiglitazone, and CD36 
only by troglitazone. GNMT and THRSP were down-regulated only by the latter. Several 
genes were down-regulated (PKLR, G6PC, ADH4) by the two glitazones. Noticeably; 15 out 215 
of the 16 genes found to be up-regulated by troglitazone at day 14; were already up-
regulated after 1 and/or 3 days. FABP4, the most overexpressed gene with fenofibrate was 
also the most overexpressed gene with troglitazone at the three time points as well as with 
rosiglitazone at 14 days, change being detected only at a p value >0.01 at days 1 and 3 with 
the latter (Fig. 5, supplemental table 2).  220 
Discussion 
Although several studies have already dealt with transcriptomic analysis of HepaRG cells, 
either in the absence or after treatment with various drugs, all have been limited to a period 
not exceeding a few days (Hart et al., 2010; Lambert et al., 2009; Rogue et al., 2012). The 
present study showed that only few genes were deregulated in differentiated HepaRG cells 225 
for 2 weeks at confluence and that both qualitative and quantitative changes in gene 
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expression were observed between the three PPAR agonists and for each of them, as a 
function of treatment duration.  
The use of 1% DMSO and 2% serum was a compromise allowing daily drug treatments, 
long-term maintenance of sufficient activity levels of the CYPs, which are known to be 230 
sensitive to DMSO. The presence of 2% serum corresponding to 0.8-0.9 mg/mL albumin can 
result in binding of drugs to proteins (Kramer et al., 2012). However, biokinetics analysis of 
several drugs has shown only limited delay, if any, in their metabolism as observed with 
chlorpromazine (Broaders et al., 2014). 
As found with Agilent microarrays (Rogue et al., 2012), the total number of expressed genes 235 
was very close from one experiment to another, using Illumina microarrays. The number of 
commonly expressed genes identified with the latter was slightly higher, i.e.12,536, n=7 
versus 11,691, n=2; this could be explained by the presence of genes encoding miRNA and 
LOC on Illumina arrays and/or the choice of different cut-off signals. Some probes can also 
be absent in either microarray, as for example UGT1A1 that was not found in the Agilent 240 
microarrays (Rogue et al., 2012).  
The total number of deregulated genes with time in culture was very limited. Indeed, only 106 
genes were found to be deregulated after 3 or 14 days, representing less than 1% of the total 
number of expressed genes. Such limited changes based on 7 independent experiments 
over a 3-year period bring further support to the high functional stability of the HepaRG cell 245 
line at confluence and to the strong inter-assay reproducibility of the data obtained with this 
cell line.  
Importantly, most deregulated genes between days 1 and 3 were repressed and related to 
the cell cycle; they remained down-regulated thereafter. This could be explained by the 
absence of marked cell proliferation when the cells are differentiated and maintained at 250 
confluence. By contrast, most other deregulated genes between days 3 and 14 were 
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overexpressed and related to xenobiotic and lipid metabolisms in agreement with previous 
observations showing increase activity of several CYPs with time at confluence; e.g. 
CYP3A4, CYP2C9 and CYP1A2 (Antherieu et al., 2010; Josse et al., 2008). This increase 
could be related to the presence of DMSO that is known to induce several major CYPs at 255 
high concentrations (Aninat et al., 2006). 
Up to now, only short-term studies on drug-induced changes in gene profiling have been 
performed with HepaRG cells. In the current work we used three PPAR agonists, fenofibrate 
troglitazone and rosiglitazone, to evaluate the influence of repeated daily treatments. Since 
these compounds have already been investigated by the transcriptomics approach in 260 
HepaRG cells and/ or primary human hepatocytes over a short period of time 
(Rakhshandehroo et al., 2009) the results were used as references in the present study. 
Although different experimental conditions (medium composition, different microarrays) were 
employed here, the major target metabolic pathways and many deregulated genes were 
similar to those identified in previous reports with the same PPAR agonists. After daily 265 
treatments for 14 days lipid and drug metabolisms remained the two main deregulated 
pathways, as previously observed after a short term exposure (Rogue et al., 2011). However, 
both qualitative and quantitative changes in gene profiling were associated with repeated 
treatments. Thus, the number of deregulated genes was marked increased with fenofibrate 
and especially rosiglitazone, and amplification of up- or down-regulation of some genes was 270 
seen with each of the three PPAR agonists after a 2-week daily treatment.  
Many PPARα target genes were found to be deregulated by fenofibrate. They included many 
genes related to lipid metabolism as well as other genes such as vinn-2 that is linked to 
inflammation and oxidative stress. Plasma vanin activity levels have been found to be 
increased significantly by fenofibrate in human subjects with type 2 diabetes (van Diepen et 275 
al., 2014). Recently, a map of the PPARα transcription regulatory network has been 
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designed for primary human hepatocytes (McMullen et al., 2014). Noticeably many major 
PPARα target genes were similarly found to be deregulated in HepaRG cells, such as 
ACOX1, CPT1A, ANGPTL4, HMGC2, PLIN2 and SLC25A20. Our data are also in line with 
those reported in human hepatocytes treated with the PPARα agonist Wy14643 280 
(Rakhshandehroo et al., 2009). 
Treatments were glitazones also showed changes in gene profiling dependent on the 
compound and the duration of treatment. Thus, the high responsiveness of  the CYP1 family 
to rosiglitazone after a short exposure (Rogue et al., 2011) was confirmed and shown to be 
maintained with repeated treatments. Noteworthy, as with fenofibrate, FAPB4 was the 285 
highest up-regulated gene observed with troglitazone at the three time points, while it was 
not modulated with rosiglitazone at days 1 and 3 (at a pv <0.01). However it also became the 
most deregulated gene with this compound at day 14. Similarly THRSP was the most or 
nearly the most repressed gene with fenofibrate and troglitazone while it was not modulated 
by rosiglitazone, except at 14 days. In addition, various qualitative and quantitative 290 
differences in gene expression levels were observed between the two glitazones in 
agreement with their quite different hepatotoxic potential. Interestingly, several genes 
previously reported to be modulated by the two glitazones in both primary human 
hepatocytes and HepaRG cells after a 24h treatment (Rogue et al., 2011) were also found to 
be altered in the present study, e.g. ANGPTL4, CD36, PLIN4 and POR. Surprisingly, the 295 
number of modulated genes by troglitazone was much lower after 14 days than 1-3 days (47 
versus 87-102); however, 15 out the 16 up-regulated genes were also found to be 
overexpressed after 1-3 days. Comparison of several concentrations of the compound and 
some qPCR analyses that are usually more sensitive than microarrays, should allow to better 
understand in vitro long-term effects.  300 
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Time-dependent quantitative changes were usually modest; those of FABP4 appearing as 
the most prominent: indeed, its overexpression was markedly higher at day 3 and/ day 14 
compared to day 1 with fenofibrate and troglitazone and its LFC reached 4.5 at day 14 
versus no change at days 1-3 with rosiglitazone.  
Another interesting observation was that many PPARα target genes, e.g. VNN1 and 305 
UGT1A1 (Senekeo-Effenberger et al., 2007), were also modulated by PPARγ agonists,  
In summary, our results show that changes in gene expression profiles in differentiated 
HepaRG cells are limited over a 2 weeks period and that daily treatments with PPAR 
agonists lead to some qualitative and quantitative changes related to the agonist and the 
duration of treatment  310 
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Figure legends  
Figure 1: Schematic representation of the experimental design. Differentiated HepaRG 405 
cells were prepared as previously described (Cerec et al., 2007): after seeding at low 
density, they were allowed to proliferate and at confluence were shifted to a medium 
containing FBS and 2% DMSO for 2 weeks. At that time, the medium was changed with 
medium containing 2% FBS and 1% DMSO for daily exposure. After 2 days, experiments 
started: cells were exposed to PPAR agonists daily for 14 days. mRNAs were prepared after 410 
1, 3 and 14 days.   
Figure 2: Expressed genes in different experiments after 1, 3 and 14 days. Numbers of 
expressed genes in different experiments (A); Percentage of commonly expressed genes 
between experiments (B); Hierarchical clustering and Venn diagrams of expressed genes as 
a function of time at confluence taking into account all experiments (C);  Principal component 415 
analysis representing all experiments (D). 
Figure 3: Effects of culture time on gene expression in HepaRG cells. Number of 
differentially expressed genes between 1, 3 and 14 days (A). Heat map taking into account 
modulated genes (FC≥1.5, ≤-1.5 with pv≤0.01) (B). Heat map taking first day as a reference 
of modulated genes involved in cell cycle, lipid and drug metabolisms (C). 420 
Figure 4: Effects of PPAR agonist exposure on HepaRG transcriptome after 1, 3 and 14 
days. Venn diagrams depicting the differentially expressed genes between drugs; three days 
are grouped (A); Number of up and down-deregulated genes by each drug  (B); Venn 
diagrams depicting the differentially expressed genes between 1, 3 and 14 days of exposure 
to fenofibrate, rosiglitazone and troglitazone (C). 425 
Figure 5: Top networks affected as a function of time by PPAR agonists. These 
networks were identified by Ingenuity Pathway Analysis® software. The actual values (log 2 
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fold change) are shown as a heatmap, where red represents increased and green decreased 
expression respectively. Modulated genes, LFC>0.58 or <-0.58, pv<0.01 at least for 1 
condition (days of treatment). 430 
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